Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding OCF Margin

The Operating Cash Flow Margin of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 19, 2026 is 34.80 %. In the previous year, Operating Cash Flow Margin was 35.44 % — a change of -1.82% (lower).

OCF Margin

34.80 %

YoY

-1.82%

Last updated:

Operating Cash Flow Margin of Tibet Rhodiola Pharmaceutical Holding is 2025 34.80 % . Operating Cash Flow Margin of Tibet Rhodiola Pharmaceutical Holding was 2024 35.44 % . It decreases by -1.82% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
28.14 CNY
Jan 1, 2019
38.98 CNY
Jan 1, 2020
31.18 CNY
Jan 1, 2021
17.14 CNY
Jan 1, 2022
32.78 CNY
Jan 1, 2023
34.53 CNY
Jan 1, 2024
35.44 CNY
Jan 1, 2025
34.80 CNY
The Tibet Rhodiola Pharmaceutical Holding OCF Margin history
YEAROCF MarginYoY
34.80 %-1.82%
35.44 %+2.66%
34.53 %+5.33%
32.78 %+91.25%
17.14 %-45.04%
31.18 %-20.00%
38.98 %+38.53%
28.14 %+181.70%
9.99 %-68.19%
31.40 %+224.20%
9.69 %-214.26%
-8.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

Operating Cash Flow Margin of Tibet Rhodiola Pharmaceutical Holding is 34.80 % in 2025.

Operating Cash Flow Margin of Tibet Rhodiola Pharmaceutical Holding changed from 35.44 % to 34.80 %, representing a -1.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Tibet Rhodiola Pharmaceutical Holding

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding